Furthermore, a decrease in plasma Aβ1-42 has recently been indicated as a biomarker of prodromal AD progression in patients with amnestic MCI positive subjects (based on Aβ1-42/P-tau in the CSF as well as ApoE ε4 genotype) versus amnesic MCI AD negative subjects [151]. Here, MAPT is linked to Alzheimer disease.